

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:) Confirmation No. 9937
)
Stephen Robert WEDGE)
)
Application No.: 10/563,439) Group Art Unit: 4173
)
Filed: January 5, 2006) Examiner: Packard, Benjamin J
)
FOR: CANCER COMBINATION THERAPY)
COMPRISING AZD2171 AND ZD1839)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, **Mail Stop AMENDMENT**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: June 6, 2008

Sir:

AMENDMENT AND RESPONSE

This is in response to the Action mailed December 10, 2007, the time for responding to which has been extended to and including June 10, 2008 by Petition and authorization for payment of fees submitted herewith. Please amend the claims as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.

The Examiner's Attention is called to the following literature references (copies attached) which are used in support of certain of the following arguments:

O'Reilly MS, Furutani K, Wu W, Onn A, Ryan A, Jürgensmeier JM, Komaki R, Herbst R, Targeted therapy against VEGFR and/or EGFR signaling with AZD2171, vandetanib, and gefitinib as part of a combined modality approach for the treatment of non-small-cell lung cancer. *J Thorac Oncol* 2007;2 (4S):abstract A5-02.

Wu W, Fujitaka K, Mandal J, Imagumbai T, Ryan A, Jurgensmeier J, Fidler IJ, O'Reilly MS and Herbst RS, AZD2171, an oral, highly potent VEGFR signaling inhibitor, in combination with gefitinib or paclitaxel: results of a study in an orthotopic human lung adenocarcinoma model. *Clin Cancer Res* 2005;11: abstract B7

Bozce, A., Formento, P., Lassalle, S., Lippens, C., Hofman, P. and Milano, G. (2007) *Br. J. Cancer* 97, 65-72., Dual inhibition of EGFR ad VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts